



RNS Number : 1143E  
EKF Diagnostics Holdings PLC  
28 June 2023

*This announcement contains inside information  
for the purposes of UK Market Abuse Regulation.*

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Directorate Change**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that Marc Davies is standing down from his role as Chief Financial Officer ("CFO") to pursue other opportunities. Marc will remain in his position to facilitate an orderly handover to his replacement for up to six months, as required.

The Company is already in advanced discussions with a suitable candidate for the CFO role, who is experienced in working with AIM-quoted healthcare companies, and is be able to commence the handover process within the next few weeks, with a view to taking on the role permanently in Q4 2023. A further announcement relating to this appointment will be made in due course.

Julian Baines remains Executive Chair and is committed to executing the Company's growth strategy, whilst also overseeing the recruitment process for a new Chief Executive Officer. An experienced senior management team continues to support the Executive Chair on an operational level, alongside significant strategic input from the Non-executive Directors.

**Julian Baines, Executive Chair of EKF, commented:** *"I would like to thank Marc for his contribution to the Company. We remain confident in the financial condition and robustness of our business and the potential value that EKF offers to shareholders. We have a well-established and growing core business in Point-of Care, and an exciting opportunity in our Life Sciences division over the coming years."*

The Company expects to give its next scheduled update on H1 trading in late July.

**EKF Diagnostics Holdings plc**  
Julian Baines, Executive Chair

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
Tel: +44 (0)29 2071 0570

**Singer Capital Markets (Nominated Adviser & Broker)**      Tel: +44 (0)20 7496 3000  
Aubrey Powell / George Tzimas / Oliver Platts

**Walbrook PR Limited**      Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)  
Paul McManus / Lianne Applegarth      Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

### **About EKF Diagnostics Holdings plc** ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAPPUUCQUPWGRM Anonymous (not verified) Directorate Change 33601841 A Wed, 06/28/2023  
- 07:00 LSE RNS Executive Changes EKF